Predictive Value of Serum pgRNA on HBeAg Clearance in Patients with Chronic Hepatitis B with Low HBeAg Levels Treated with Pegylated Interferon
Download PDF
$currentUrl="http://$_SERVER[HTTP_HOST]$_SERVER[REQUEST_URI]"

Keywords

Serum pgRNA
Pegylated interferon
Low HBeAg level
Chronic hepatitis B
HBeAg clearance
Predictive value

DOI

10.26689/jcnr.v7i4.4906

Submitted : 2023-06-29
Accepted : 2023-07-14
Published : 2023-07-29

Abstract

 Objective: To study the predictive value of serum pregenomic RNA (pgRNA) on HBeAg clearance in patients with chronic hepatitis B with low HBeAg levels during pegylated interferon therapy. Methods: Twenty chronic hepatitis B patients with HBeAg positive and quantitative <50S/CO were selected for this study. The subjects underwent pegylated interferon therapy for 48–96 weeks and were followed up in the outpatient clinic after treatment. The patients were then divided into groups based on whether their HbeAg turned negative. The predictive ability of each indicator for HBeAg negative conversion was evaluated in the HBeAg negative group and the HBeAg positive group. Results: The results of logistic regression analysis suggested that pgRNA and HBcrAg were better indicators for predicting the clearance of HBeAg after treatment. Conclusion: For patients with chronic hepatitis B with low HBeAg levels, pgRNA is a good indicator in predicting HBeAg clearance during pegylated interferon therapy.

References

Liu Z, Liu M, Gong H, et al., 2022, Predictive Significance of Serum pgRNA on HBeAg Clearance in Patients with Chronic Hepatitis B with Low HBeAg Levels Treated with Pegylated Interferon. Journal of Army Medical University, 44(02): 155–161.

Society of Infectious Diseases, Chinese Medical Association, Society of Hepatology, Chinese Medical Association, 2019, Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition). Chinese Journal of Infectious Diseases, 37(12): 711–736. https://www.doi.org/10.3760/cma.j.issn.1000-6680.2019.12.003

Li X, Li L, Yuan S, et al., 2021, Analysis of the Level of Serum Hepatitis B Virus Pregenome RNA in 70 Cases of Chronic Hepatitis B Patients with Negative Hepatitis B Virus DNA. Chinese Journal of Infectious Diseases, 39(9): 4.

Yan J, Wang C, Liu J, et al., 2022, The Predictive Value of Serum Hepatitis B Virus Pregenome RNA Levels on Nucleoside (acid) Analogue-naïve Chronic Hepatitis B Patients. Practical Hepatology Journal, 25(1): 4.

Shen J, Fang J, Ma C, et al., 2021, Study on the Relationship and Clinical Significance of Serum HBV RNA, HBeAg Seroconversion and Virological Response in Patients with Chronic Hepatitis B Treated with Pegylated Interferon ?-2a. Journal of Microcirculation, 31(4): 53–58.

Jia R, Wang W, Gao Y, et al., 2021, Early Decline in Serum RANTES can Predict HBsAg Clearance in Patients with Chronic Hepatitis B Treated with Nucleoside (Acid) Analogues Combined with Pegylated Interferon ?. Journal of Diseases, 29(7): 7.

Zeng Y, Wang C, He Y, et al., 2022, Clinical Significance of Serum Hepatitis B Virus Pregenomic RNA in Patients with Chronic Hepatitis B Treated with Nucleoside (Acid) Analogs. Journal of Clinical Internal Medicine, 39(11): 4.

Qin Y, Wang L, Zhang Q, 2022, Effect of Pegylated Interferon ? Treatment on Serum Inflammatory Factor Levels in Patients with Chronic Hepatitis B. Journal of Clinical and Experimental Medicine, 21(23): 2501–2505.

Qu H, Dong J, Shi L, 2022, The Effect of Pegylated Interferon-? on the Levels of HBsAg, Tfh Cells and B Cell Markers in Patients with Hepatitis B. International Journal of Laboratory Medicine, 43(18): 2288–2291 + 2297.

Wu Y, Cheng C, Lai W, et al., 2021, Effect of Tenofovir Combined with Pegylated Interferon ?-2b Injection on HBeAg Seroconversion Rate and Negative Conversion Rate in Patients with Chronic Hepatitis B. Advances in Modern Biomedicine, 21(10): 1938–1941.

Cao Y, 2021, Value Analysis of Pegylated Interferon a-2a and Hepatitis B Vaccine Combined Treatment of Chronic Hepatitis B. Diet and Health Care, 2021(5): 37.

Wu Y, Zhang S, Lu M, 2021, Establishment of a Baseline Score Prediction Model for Peginterferon ?-2a in HBeAg-Positive Chronic Hepatitis B Patients. Chinese Journal of Microecology, 33(10): 1185–1190.

Qin Y, Wang L, Zhang Q, 2022, Effect of Pegylated Interferon ? Treatment on Serum Inflammatory Factor Levels in Patients with Chronic Hepatitis B. Journal of Clinical and Experimental Medicine, 21(23): 2501–2505.

Li C, Zhao W, Liu S, et al., 2022, Observation on Curative Effect of Nucleoside Analogs Sequentially Combined with Pegylated Interferon ?-2b in the Treatment of Patients with Chronic Hepatitis B with Low Levels of Hepatitis B Surface Antigen. Journal of Xinxiang Medical College, 39(4): 323–329.

Zhu X, Lin Z, Wang L, 2022, Correlation Between the Expression Level of HBV pgRNA and the Response to Nucleoside (Glycoside) Acid Analog Therapy in Patients with Chronic Hepatitis B. Journal of Practical Medicine, 38(20): 2585–2589 + 2596.

Zeng Y, Wang C, He Y, et al., 2022, Clinical Significance of Serum Hepatitis B Virus Pregenomic RNA in Patients with Chronic Hepatitis B Treated with Nucleoside (Acid) Analogues. Journal of Clinical Internal Medicine, 39(11): 751–754.